关于乳腺病变术前诊断程序的共识文件。

IF 4.4 Q1 PATHOLOGY
Stefano Marletta, Isabella Castellano, Francesca Caumo, Carmen Criscitiello, Patrizia Frittelli, Donatella Santini, Daniela Terribile, Daniela Bernardi, Marina Bortul, Massimo Calabrese, Giuseppe Catanuto, Maria Grazia Cattani, Leopoldo Costarelli, Giulia D'Amati, Nicola Fusco, Oreste Gentilini, Moira Ragazzi, Gianni Saguatti, Alfredo Santinelli, Cristian Scatena, Grazia Sciancalepore, Francesca Pietribiasi, Anna Sapino, Antonio Rizzo
{"title":"关于乳腺病变术前诊断程序的共识文件。","authors":"Stefano Marletta, Isabella Castellano, Francesca Caumo, Carmen Criscitiello, Patrizia Frittelli, Donatella Santini, Daniela Terribile, Daniela Bernardi, Marina Bortul, Massimo Calabrese, Giuseppe Catanuto, Maria Grazia Cattani, Leopoldo Costarelli, Giulia D'Amati, Nicola Fusco, Oreste Gentilini, Moira Ragazzi, Gianni Saguatti, Alfredo Santinelli, Cristian Scatena, Grazia Sciancalepore, Francesca Pietribiasi, Anna Sapino, Antonio Rizzo","doi":"10.32074/1591-951X-1113","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, percutaneous sampling via core needle or vacuum-assisted biopsy is the primary choice to guide the management of patients with clinical or screen-detected breast lesions. Preoperative biopsies allow physicians to get pathological diagnoses as well as key prognostic and predictive data about the nature of the investigated process. Namely, adequate biopsy sampling is crucial for assigning lesions to one diagnostic category (B1-B5). Similarly, evaluating morphological (histotype, vascular invasion, necrosis, etc.) and immunohistochemical/molecular features (ER, PR, Ki-67, and HER2) is the key to address the most effective therapies, especially in the neoadjuvant setting. The multidisciplinary team should always discuss the results of percutaneous biopsies, whose global integration with clinical and radiological findings will drive the adoption of specific treatment options, particularly for uncertain (B3) and suspicious/malignant (B4-B5) lesions.</p><p><p>In the present work, we report a comprehensive overview of breast percutaneous biopsy techniques, diagnostic categories, and multidisciplinary management based on widely acknowledged evidence of good clinical practice.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 3","pages":"178-198"},"PeriodicalIF":4.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236140/pdf/","citationCount":"0","resultStr":"{\"title\":\"Consensus document on preoperative diagnostic procedures in breast lesions.\",\"authors\":\"Stefano Marletta, Isabella Castellano, Francesca Caumo, Carmen Criscitiello, Patrizia Frittelli, Donatella Santini, Daniela Terribile, Daniela Bernardi, Marina Bortul, Massimo Calabrese, Giuseppe Catanuto, Maria Grazia Cattani, Leopoldo Costarelli, Giulia D'Amati, Nicola Fusco, Oreste Gentilini, Moira Ragazzi, Gianni Saguatti, Alfredo Santinelli, Cristian Scatena, Grazia Sciancalepore, Francesca Pietribiasi, Anna Sapino, Antonio Rizzo\",\"doi\":\"10.32074/1591-951X-1113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Currently, percutaneous sampling via core needle or vacuum-assisted biopsy is the primary choice to guide the management of patients with clinical or screen-detected breast lesions. Preoperative biopsies allow physicians to get pathological diagnoses as well as key prognostic and predictive data about the nature of the investigated process. Namely, adequate biopsy sampling is crucial for assigning lesions to one diagnostic category (B1-B5). Similarly, evaluating morphological (histotype, vascular invasion, necrosis, etc.) and immunohistochemical/molecular features (ER, PR, Ki-67, and HER2) is the key to address the most effective therapies, especially in the neoadjuvant setting. The multidisciplinary team should always discuss the results of percutaneous biopsies, whose global integration with clinical and radiological findings will drive the adoption of specific treatment options, particularly for uncertain (B3) and suspicious/malignant (B4-B5) lesions.</p><p><p>In the present work, we report a comprehensive overview of breast percutaneous biopsy techniques, diagnostic categories, and multidisciplinary management based on widely acknowledged evidence of good clinical practice.</p>\",\"PeriodicalId\":45893,\"journal\":{\"name\":\"PATHOLOGICA\",\"volume\":\"117 3\",\"pages\":\"178-198\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236140/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PATHOLOGICA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32074/1591-951X-1113\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-1113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目前,经皮穿刺穿刺或真空辅助活检是指导临床或筛查发现乳腺病变患者管理的主要选择。术前活检允许医生得到病理诊断以及关键的预后和预测数据的性质的调查过程。也就是说,充分的活检取样对于将病变划分为一个诊断类别(B1-B5)至关重要。同样,评估形态学(组织型、血管侵袭、坏死等)和免疫组织化学/分子特征(ER、PR、Ki-67和HER2)是确定最有效治疗方法的关键,尤其是在新辅助治疗中。多学科团队应经常讨论经皮活检的结果,其与临床和放射学结果的整体整合将推动采用特定的治疗方案,特别是对于不确定(B3)和可疑/恶性(B4-B5)病变。在目前的工作中,我们报告了基于广泛认可的良好临床实践证据的乳房经皮活检技术,诊断类别和多学科管理的全面概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Consensus document on preoperative diagnostic procedures in breast lesions.

Currently, percutaneous sampling via core needle or vacuum-assisted biopsy is the primary choice to guide the management of patients with clinical or screen-detected breast lesions. Preoperative biopsies allow physicians to get pathological diagnoses as well as key prognostic and predictive data about the nature of the investigated process. Namely, adequate biopsy sampling is crucial for assigning lesions to one diagnostic category (B1-B5). Similarly, evaluating morphological (histotype, vascular invasion, necrosis, etc.) and immunohistochemical/molecular features (ER, PR, Ki-67, and HER2) is the key to address the most effective therapies, especially in the neoadjuvant setting. The multidisciplinary team should always discuss the results of percutaneous biopsies, whose global integration with clinical and radiological findings will drive the adoption of specific treatment options, particularly for uncertain (B3) and suspicious/malignant (B4-B5) lesions.

In the present work, we report a comprehensive overview of breast percutaneous biopsy techniques, diagnostic categories, and multidisciplinary management based on widely acknowledged evidence of good clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PATHOLOGICA
PATHOLOGICA PATHOLOGY-
CiteScore
5.90
自引率
5.70%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信